Xingming Deng, MD, PhD
Professor and Chair in Cancer Biology
Department of Radiation Oncology, Emory University School of Medicine
Director of Discovery Theme
Discovery and Development Therapeutics Research Program, Winship Cancer Institute of Emory University
- Xingming Deng, MD, PhD specializes in cancer research, including lung, head/neck and blood cancers.
- Major research interests are to uncover cell death mechanisms, especially Bcl2 family, to investigate molecular and signaling mechanisms of DNA repair, DNA replication stress, genomic instability and carcinogenesis, to study signaling mechanisms of tumor invasion/metastasis, and to develop novel small molecule anti-cancer agents and new therapeutic strategies for cancer therapy by targeting apoptosis and DNA repair signaling pathways, and to target novel signal mechanisms of PD-1 and PD-L1 for immunotherapy. Additionally, Dr. Deng is also studying environmental carcinogenesis, specifically mechanisms of tobacco smoke- or space radiation-induced DNA damage, genomic instability and carcinogenesis at the cellular, molecular and animal levels.
- Dr. Deng's research will contribute to development of new agents and strategies for treatment of cancer by targeting apoptosis and DNA repair mechanisms.
- His top research accomplishments include uncovering new mechanism of treatment resistance of cancer and identifying novel small molecule anti-cancer agents that can reverse treatment resistance.
- Dr. Deng is a core member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute of Emory University.
Dr. Deng is a faculty member engaged in cancer research and currently holds the appointment of Professor and is the inaugural Chair in Cancer Biology in the Department of Radiation Oncology at Emory University School of Medicine. From 2009 to 2017, he was Associate Professor in the Department of Radiation Oncology at Emory University School of Medicine. Dr. Deng completed his postdoctoral training at the University of Texas Medical Branch. He was an assistant professor in Division of Hematology/Oncology, Department of Medicine at University of Florida before joining Emory.
He is an active member of the American Association for Cancer Research. He has been the recipient of eighteen research grants, including Clinical Innovator Awards from Flight Attendant Medical Research Institute, NASA research grant, and several R01 grants from NIH/NCI. Dr. Deng also teaches the advanced course for cancer biology graduate students and medical residents. He has mentored a number of undergraduates, graduates, postdoctoral fellows, medical residents and junior faculty members in University of Florida and Emory University. Dr. Deng currently serves as a Course Director in Advanced Graduate Cancer Biology Program in Emory Laney Graduate School. He has served on several national and international grant review panels. He also serves on the editorial board for several journals and is frequently invited to serve as reviewer for numerous biomedical journals.
Dr. Deng received his MD/PhD at Hunan Medical University and Beijing Medical University in China. He completed his postdoctoral training in Molecular Biology at the University of Texas Medical Branch.
Dr. Deng has received a number of awards in his career including AACR-Bristol-Myers Squibb Young Investigator Award, three ASH Travel Awards, Basic Science Research Winner, Excellence in Research Award, Emory University Winship Scholar, and the Emory 1% Award with NIH R01 grant scoring in the top 1% at peer review.
Deng has published many excellent research articles in high impact journals such as Molecular Cell, Cancer Cell, Nature Communications, The Journal of Clinical Investigation, PNAS, Cancer Research, Cell Death Differentiation, Nucleic Acid Research, MCB, Blood, and JBC. He has also obtained three patents for new anticancer drug discovery.